CPI-613 (devimistat)
T-cell Lymphomas (Peripheral, Cutaneous)
Key Facts
About Rafael Holdings
Rafael Holdings is a clinical-stage oncology company leveraging its expertise in cancer metabolism to develop innovative therapeutics. Its core asset, CPI-613, is a lipoate analog that disrupts key mitochondrial enzymes, inducing selective cancer cell death. The company is advancing CPI-613 through multiple clinical trials, primarily in combination regimens, and maintains a strategic focus on aggressive and rare cancers with high unmet need.
View full company profile